Digital medical services platform Teladoc Health (NYSE: TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 15.5% above analysts’ consensus estimates.

Is now the time to buy TDOC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Teladoc’s second quarter results were met with a significant negative market reaction, as revenue declined year-over-year and missed Wall Street expectations. Management attributed the underperformance primarily to accelerated declines in its BetterHelp cash pay business, driven by a faster-than-anticipated consumer shift toward insurance and capacity constraints in its provider network. CEO Charles Divita acknowledged, “the increasing speed of consumer movement towards insurance provider capacity and network constraints against this increased demand... became more pronounced and persistent than the assumptions underlying our prior outlook.” The company’s integrated care segment, however, saw moderate revenue growth, supported by chronic care enrollment and international demand.

Looking ahead, Teladoc’s updated full-year guidance reflects continued pressure on the BetterHelp cash pay model, with the company focusing on accelerating the transition toward an in-network insurance approach. Management aims to expand provider capacity and enhance its insurance platform but cautioned that these initiatives will take time to impact results. Divita explained that the company is “investing ahead of the opportunity here, so we see operating leverage kick in as insurance continues to scale further.” Near-term, advertising spending will be reduced to align with available network capacity, and the company expects the insurance segment to become a larger driver of growth and profitability over the coming years.

Key Insights from Management’s Remarks

Management cited the rapid consumer preference shift to insurance in the BetterHelp segment, capacity limitations within the therapist network, and strategic resource reallocation as central to both the quarter’s underperformance and the revised outlook.

• Accelerated insurance adoption: The BetterHelp user base shifted to insurance coverage faster than management had modeled, with approximately 70% of potential users now preferring insurance, leading to a decline in cash pay users and revenue.
• Provider network constraints: Despite credentialing over 8,000 therapists and expanding national insurance availability, provider capacity could not keep pace with increased insurance demand, limiting the company’s ability to convert interest into completed sessions and revenue.
• Advertising spend realignment: Teladoc deliberately reduced advertising for BetterHelp to avoid generating cash pay demand that could not be served, and is now focusing on insurance-oriented marketing, which is expected to lower customer acquisition costs over time.
• International deprioritization: The company has temporarily shifted resources away from international BetterHelp expansion to focus on scaling U.S. insurance offerings, though management reiterated long-term international opportunities remain.
• Integrated care innovation: Teladoc launched Teladoc 1, a new connected care model, supported by the Pulse intelligence engine, aiming to provide coordinated care for cardiometabolic health and eventually broader populations, which management views as a key differentiator for future client wins.

Drivers of Future Performance

Teladoc’s outlook is shaped by its pivot to insurance within BetterHelp, ongoing capacity expansion, and continued innovation in integrated care, with margin trends impacted by changing revenue mix and investment priorities.

• Scaling therapist network: Management’s top priority is closing the supply gap for in-network therapists, with ongoing recruitment, delegated credentialing, and investments in onboarding and platform tools to support rising insurance user demand.
• Advertising and profitability shifts: Reduced advertising spend is expected to lower cash pay acquisition but improve efficiency, while insurance revenue growth may pressure gross margins in the near term, with the company targeting improved EBITDA margins as the insurance mix expands.
• Integrated care and product launches: Continued product innovation—including Teladoc 1 and expanded chronic care bundles—should support moderate growth in integrated care, but management notes the environment remains competitive and some large contract implementations have been deferred.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will closely track (1) progress in expanding therapist network capacity and improving insurance user conversion, (2) the impact of reduced advertising spend on cash pay trends and overall BetterHelp profitability, and (3) adoption of Teladoc 1 and chronic care bundles in integrated care. Developments in international strategy and the scale of insurance-driven growth will also be key indicators of execution.

Teladoc currently trades at $7.55, down from $9.18 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.